Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Checkpoint Inhibitor Treatment naïve Adults With Unresectable or Metastatic Melanoma

Next Previous
X
Search
Trial Profile

An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Checkpoint Inhibitor Treatment naïve Adults With Unresectable or Metastatic Melanoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EVX 01 (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Evaxion Biotech

    • Most Recent Events

    • 03 Oct 2024 According to an Evaxion Biotech media release, 79% of the AI-Immunology™ predicted vaccine targets triggered a tumor-specific immune response in this study, a significant increase from 58% observed in the EVX-01 phase 1 trial.
    • 16 Sep 2024 According to an Evaxion Biotech media release, the data was presented during the weekend at a poster session at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.
    • 16 Sep 2024 According to an Evaxion Biotech media release, final results are expected in the third quarter of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top